Yongfeng Piao1,2, Caineng Cao1,2, Yuanfan Xu3, Shuang Huang1,2, Feng Jiang1,2, Ting Jin1,2, Qifeng Jin1,2, Yonghong Hua1,2, Qiaoying Hu1,2, Xiaozhong Chen4,5. 1. Department of Radiation Oncology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Beijing, China. 2. Key Laboratory of Head and Neck Cancer Translational Research of Zhejiang Province, No 1, East Banshan Road, Gongshu District, Hangzhou, 310022, China. 3. Hangzhou Universal Medical Imagine Diagnostion Center, Hangzhou, Zhejiang, China. 4. Department of Radiation Oncology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Beijing, China. chenxiaozhong2016@163.com. 5. Key Laboratory of Head and Neck Cancer Translational Research of Zhejiang Province, No 1, East Banshan Road, Gongshu District, Hangzhou, 310022, China. chenxiaozhong2016@163.com.
Abstract
PURPOSE: The aim of this pilot study was to evaluate the accuracy of 18 fluorodeoxyglucose (FDG) PET/MR imaging in detection and staging of recurrent or metastatic NPC. PATIENTS AND METHODS: The PET/MR scans of 60 patients with clinically diagnosed recurrent or metastatic NPC between April 2017 and November 2019 were included in this study. Findings were evaluated according to the eighth edition of the American Joint Committee on Cancer staging system. Final diagnosis was confirmed at biopsy or imaging follow-up for at least 6 months. RESULTS: Of the 60 patients, 25, 26 and 42 had developed local lesions, regional nodal metastases and distant metastases, respectively. The overall accuracy of PET/MR imaging for staging of recurrent or metastatic NPC was 88.3%. CONCLUSIONS: For recurrent or metastatic NPC, 18 FDG PET/MRI might serve as a single-step staging modality.
PURPOSE: The aim of this pilot study was to evaluate the accuracy of 18 fluorodeoxyglucose (FDG) PET/MR imaging in detection and staging of recurrent or metastatic NPC. PATIENTS AND METHODS: The PET/MR scans of 60 patients with clinically diagnosed recurrent or metastatic NPC between April 2017 and November 2019 were included in this study. Findings were evaluated according to the eighth edition of the American Joint Committee on Cancer staging system. Final diagnosis was confirmed at biopsy or imaging follow-up for at least 6 months. RESULTS: Of the 60 patients, 25, 26 and 42 had developed local lesions, regional nodal metastases and distant metastases, respectively. The overall accuracy of PET/MR imaging for staging of recurrent or metastatic NPC was 88.3%. CONCLUSIONS: For recurrent or metastatic NPC, 18 FDG PET/MRI might serve as a single-step staging modality.
Authors: Anne W M Lee; Wai Tong Ng; Jimmy Y W Chan; June Corry; Antti Mäkitie; William M Mendenhall; Alessandra Rinaldo; Juan P Rodrigo; Nabil F Saba; Primož Strojan; Carlos Suárez; Jan B Vermorken; Sue S Yom; Alfio Ferlito Journal: Cancer Treat Rev Date: 2019-08-21 Impact factor: 12.111
Authors: Quynh Thu Le; A Dimitrios Colevas; Brian O'Sullivan; Anne W M Lee; Nancy Lee; Brigette Ma; Lillian L Siu; John Waldron; Chwee-Ming Lim; Nadeem Riaz; Jean Lynn; Shakun Malik Journal: J Natl Cancer Inst Date: 2019-07-01 Impact factor: 13.506
Authors: Anne W Lee; Wai Tong Ng; Jian Ji Pan; Sharon S Poh; Yong Chan Ahn; Hussain AlHussain; June Corry; Cai Grau; Vincent Grégoire; Kevin J Harrington; Chao Su Hu; Dora L Kwong; Johannes A Langendijk; Quynh Thu Le; Nancy Y Lee; Jin Ching Lin; Tai Xiang Lu; William M Mendenhall; Brian O'Sullivan; Enis Ozyar; Lester J Peters; David I Rosenthal; Yoke Lim Soong; Yungan Tao; Sue S Yom; Joseph T Wee Journal: Radiother Oncol Date: 2017-11-15 Impact factor: 6.280